• 1 Post
  • 857 Comments
Joined 1 year ago
cake
Cake day: July 20th, 2023

help-circle












  • It sounds like it didn’t get reviewed By the publisher and he seems genuinely apologetic.

    Miami New Times publisher Adam Simon tells Axios the ad is unacceptable and he’s changing the alt weekly’s ad review process.

    • Normally, he said, staffers — including himself — review ads prior to publication. But in this case, the ad came in past their deadline and Simon did not review it.
    • The New Times will no longer take ads so late that they can’t be reviewed, he said.
    • “Naturally, had I seen it, which I should have, I would not have let it run as is.”

    Who knows for sure, but I was expecting whoever ran the ad to either be a supporter or completely indifferent. It was a nice surprise to see them also be upset instead.


  • This is a hard one. I think we can all agree that the people who need it should have it and the people who don’t…don’t…especially if their easy access to the drug pretty much guarantees a shortage of the drug for those who do need it.

    I need it. And when there was a shortage just as we were forced to return to the office after Covid wfh, it was a nightmare. I don’t know for sure that this company was handing out prescriptions to whoever would pay or if they were mostly legitimate, but I imagine that it’s somewhere in between the two. And I do know that we will never be able to have a rational discussion about it between health professionals and the DEA/FDA, etc.

    So, a lot of people who need it won’t get it either due to shortages or due to not being able to access a prescription for whatever reason.

    Some people will continue to access it who don’t need it, but on a level that guarantees sporadic shortages for others.

    No one wins other than those profiting either by selling prescriptions or by selling the drugs themselves at a much higher price than they paid for it using said prescriptions.

    Rinse, wash, repeat.